Glenmark Life Sciences Ltd

Alivus Life Sciences Limited has announced the acquisition of a 76% majority stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. IQGenX, a custom research organization founded in 2016, specializes in formulation development for oral solids, sterile injectables, and ophthalmic solutions across regulated and semi-regulated markets. This acquisition aims to integrate Alivus's API expertise with IQGenX's formulation capabilities, creating an end-to-end platform for complex drug delivery formats. The move is expected to expand Alivus's global customer base, enhance its CDMO services, and focus on niche oncology assets for out-licensing. The deal is subject to customary closing conditions and is anticipated to conclude by the end of the current calendar year.

Alivus Life Sciences Limited announced its Board of Directors has approved the acquisition of a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately ₹9.12 crores. The acquisition aims to expand Alivus's offerings in the API and CDMO space by integrating IQGEN-X Pharma's formulation development capabilities for oral solids, sterile injectables, and ophthalmic solutions. The transaction is expected to be completed by December 6, 2026, subject to customary closing conditions. IQGEN-X Pharma reported a turnover of INR 348 Lacs for the financial year ended March 31, 2026. This acquisition is not considered a related party transaction.

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Ltd) has submitted its Integrated Annual Report for the Financial Year 2025-26, in compliance with SEBI LODR Regulations. The report, prepared according to the Integrated Reporting Framework and GRI standards, offers a holistic view of the company's strategy, governance, performance, and outlook, emphasizing value creation across six capitals: Financial, Manufactured, Intellectual, Human, Social & Relationship, and Natural. The report covers both financial and non-financial performance from April 1, 2025, to March 31, 2026. Alivus is leveraging its expertise in chemistry and manufacturing to expand into adjacent business areas, aiming to enhance its portfolio and customer relationships. The company has obtained independent assurance for its BRSR Core KPIs from BSI.

Alivus Life Sciences Ltd has announced its 15th Annual General Meeting (AGM) to be held on Tuesday, September 8, 2026, at 3:00 p.m. IST via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting will cover ordinary business including the adoption of audited financial statements for FY26, declaration of a final dividend of ₹5 per equity share, and the re-appointment of Mr. Hiren Patel as a Director. Special business includes ratifying the remuneration for Cost Auditors, Kirit Mehta & Co. LLP, for FY27. Shareholders can exercise their voting rights through e-voting from September 4 to September 7, 2026. The cut-off date for e-voting eligibility is September 1, 2026.

Alivus Life Sciences Ltd has announced Tuesday, September 1, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹5.00 per equity share. This dividend is for the financial year ended March 31, 2026, and was recommended by the Board of Directors on May 14, 2026. Shareholders will receive the dividend, subject to tax deduction, on or after Friday, September 11, 2026, provided it is approved at the upcoming Fifteenth Annual General Meeting (AGM) scheduled for Tuesday, September 8, 2026. The AGM will be conducted via Video Conferencing or Other Audio-Visual Means.

Alivus Life Sciences Ltd has announced its 15th Annual General Meeting (AGM) will be held on September 8, 2026, via Video Conferencing. The company's Board of Directors has recommended a final dividend of ₹5.00 per equity share for the financial year ended March 31, 2026. The record date for determining entitlement to this dividend has been fixed as September 1, 2026. If approved at the AGM, the dividend payment is scheduled for on or after September 11, 2026, subject to tax deductions.

Alivus Life Sciences Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved the results in a meeting held on July 30, 2026. The company's results were subjected to a limited review by the statutory auditors. Alivus Life Sciences operates in a single reporting segment: Active Pharmaceutical Ingredient (API). The company also reported an increase in paid-up equity share capital due to the allotment of shares under its Employee Stock Option Scheme.

Alivus Life Sciences Limited announced its financial results for the first quarter ended June 30, 2026 (Q1FY27). The company reported a revenue from operations of ₹6,404 Mn, a 6.4% year-over-year (YoY) growth, primarily driven by its non-GPL business which saw a 26.5% YoY increase. EBITDA for the quarter stood at ₹2,341 Mn, up 29.1% YoY, with margins at 36.6%. Profit After Tax (PAT) reached ₹1,601 Mn, marking a 31.8% YoY growth and achieving PAT margins of 25.0%. The company generated ₹901 Mn in free cash flow, ending the quarter with ₹8,802 Mn in cash and cash equivalents. Alivus Life Sciences reaffirmed its FY27 revenue growth guidance of 10%-12% and EBITDA margin target of 30%-32%. The company also provided updates on its capacity expansion projects in Solapur and the development of a new R&D facility in Taloja.

Alivus Life Sciences Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved the results during a meeting held on July 30, 2026. The company's results were subjected to a limited review by the statutory auditors. The company operates in a single reporting segment: Active Pharmaceutical Ingredient (API). During the quarter, the company allotted 3,100 equity shares under its Employee Stock Option Scheme, increasing its paid-up equity share capital.

Alivus Life Sciences Ltd has announced the closure of its trading window from July 1, 2026, to August 1, 2026, inclusive. This closure is in preparation for the board meeting scheduled for July 30, 2026, where the unaudited financial results for the quarter ended June 30, 2026, will be considered and approved. The company has informed its designated persons about this trading window restriction as per SEBI regulations.